269 related articles for article (PubMed ID: 26427607)
1. Impaired bone remodeling and its correction by combination therapy in a mouse model of mucopolysaccharidosis-I.
Kuehn SC; Koehne T; Cornils K; Markmann S; Riedel C; Pestka JM; Schweizer M; Baldauf C; Yorgan TA; Krause M; Keller J; Neven M; Breyer S; Stuecker R; Muschol N; Busse B; Braulke T; Fehse B; Amling M; Schinke T
Hum Mol Genet; 2015 Dec; 24(24):7075-86. PubMed ID: 26427607
[TBL] [Abstract][Full Text] [Related]
2. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
[TBL] [Abstract][Full Text] [Related]
3. Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model.
Santi L; De Ponti G; Dina G; Pievani A; Corsi A; Riminucci M; Khan S; Sawamoto K; Antolini L; Gregori S; Annoni A; Biondi A; Quattrini A; Tomatsu S; Serafini M
Mol Genet Metab; 2020 Jul; 130(3):197-208. PubMed ID: 32439268
[TBL] [Abstract][Full Text] [Related]
4. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
[TBL] [Abstract][Full Text] [Related]
5. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow.
Zheng Y; Rozengurt N; Ryazantsev S; Kohn DB; Satake N; Neufeld EF
Mol Genet Metab; 2003 Aug; 79(4):233-44. PubMed ID: 12948739
[TBL] [Abstract][Full Text] [Related]
6. Bone Remodeling in an Mps-1h Girl after Hematopoietic Stem Cell Transplantation along with Enzymatic Replacement Therapy.
Tummolo A; Brunetti G; Piacente L; Marzollo A; Biffi A; Burlina A; Faienza MF
Endocr Metab Immune Disord Drug Targets; 2022; 22(14):1425-1432. PubMed ID: 35619307
[TBL] [Abstract][Full Text] [Related]
7. Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.
Squeri G; Passerini L; Ferro F; Laudisa C; Tomasoni D; Deodato F; Donati MA; Gasperini S; Aiuti A; Bernardo ME; Gentner B; Naldini L; Annoni A; Biffi A; Gregori S
Mol Ther; 2019 Jul; 27(7):1215-1227. PubMed ID: 31060789
[TBL] [Abstract][Full Text] [Related]
8. Mucopolysaccharidosis type I.
Wraith JE; Jones S
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
[TBL] [Abstract][Full Text] [Related]
9. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice.
Chung S; Ma X; Liu Y; Lee D; Tittiger M; Ponder KP
Mol Genet Metab; 2007 Feb; 90(2):181-92. PubMed ID: 16979922
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
[TBL] [Abstract][Full Text] [Related]
11. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene.
Hartung SD; Frandsen JL; Pan D; Koniar BL; Graupman P; Gunther R; Low WC; Whitley CB; McIvor RS
Mol Ther; 2004 Jun; 9(6):866-75. PubMed ID: 15194053
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy in mucopolysaccharidosis type I.
Miebach E
Acta Paediatr Suppl; 2005 Mar; 94(447):58-60; discussion 57. PubMed ID: 15895714
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
[TBL] [Abstract][Full Text] [Related]
15. Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.
Wang D; Shukla C; Liu X; Schoeb TR; Clarke LA; Bedwell DM; Keeling KM
Mol Genet Metab; 2010 Jan; 99(1):62-71. PubMed ID: 19751987
[TBL] [Abstract][Full Text] [Related]
16. Evidence that glycosaminoglycan storage and collagen deposition in the cauda epididymidis does not impair sperm viability in the Mucopolysaccharidosis type I mouse model.
do Nascimento CC; Aguiar O; Viana GM; D Almeida V
Reprod Fertil Dev; 2020 Feb; 32(3):304-312. PubMed ID: 31679559
[TBL] [Abstract][Full Text] [Related]
17. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.
Ou L; Przybilla MJ; Koniar B; Whitley CB
Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892
[TBL] [Abstract][Full Text] [Related]
18. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB
Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cells do not prevent antibody responses against human α-L-iduronidase when used to treat mucopolysaccharidosis type I.
Martin PK; Stilhano RS; Samoto VY; Takiya CM; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; Marques FL; Otake AH; Chammas R; Han SW
PLoS One; 2014; 9(3):e92420. PubMed ID: 24642723
[TBL] [Abstract][Full Text] [Related]
20. High-dose enzyme replacement therapy in murine Hurler syndrome.
Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
